Aptorum Shareholders Approve DiamiR Biosciences Merger, Advancing Key Strategic Deal
APM sits 68% above its 52-week low of $0.65 on elevated volume (5.9× avg).
Summary
Aptorum Group shareholders have approved the proposed merger with DiamiR Biosciences. This is a critical step towards completing the reverse merger, which has been extensively detailed in multiple S-4/A and 6-K filings over the past few months. The transaction is highly material for Aptorum, especially given the going concern warning noted in its recent 20-F filing. This approval moves the company closer to executing a key strategic initiative. The merger agreement's termination date was previously extended to June 30, 2026, so this approval is timely. Investors will now watch for the final closing of the merger.
At the time of this announcement, APM was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.65 to $4.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.